Baillie Gifford & Co. Reduces Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Baillie Gifford & Co. cut its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 4.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 422,763 shares of the company's stock after selling 18,300 shares during the quarter. Baillie Gifford & Co. owned 0.53% of CRISPR Therapeutics worth $26,465,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Price T Rowe Associates Inc. MD increased its holdings in shares of CRISPR Therapeutics by 158.5% during the second quarter. Price T Rowe Associates Inc. MD now owns 3,014,551 shares of the company's stock valued at $183,194,000 after acquiring an additional 1,848,437 shares in the last quarter. ARK Investment Management LLC increased its stake in CRISPR Therapeutics by 19.2% in the 4th quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company's stock worth $534,360,000 after buying an additional 1,372,986 shares in the last quarter. State Street Corp raised its stake in CRISPR Therapeutics by 228.8% during the 2nd quarter. State Street Corp now owns 1,569,860 shares of the company's stock valued at $95,400,000 after purchasing an additional 1,092,384 shares during the period. BlackRock Inc. lifted its holdings in shares of CRISPR Therapeutics by 79.2% in the first quarter. BlackRock Inc. now owns 2,278,774 shares of the company's stock worth $143,038,000 after buying an additional 1,007,246 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in CRISPR Therapeutics by 261.4% in the 1st quarter. Vanguard Group Inc. now owns 1,217,289 shares of the company's stock worth $76,410,000 after purchasing an additional 880,463 shares in the last quarter. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Stock Up 1.9 %

CRISPR Therapeutics stock traded up $1.17 during mid-day trading on Thursday, hitting $62.91. 1,040,172 shares of the company's stock traded hands, compared to its average volume of 1,879,889. The firm has a 50 day moving average price of $74.09 and a 200 day moving average price of $62.88. The company has a market cap of $5.05 billion, a PE ratio of -32.10 and a beta of 1.76. CRISPR Therapeutics AG has a one year low of $37.55 and a one year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.15 by $0.95. The business had revenue of $201.20 million for the quarter, compared to the consensus estimate of $148.72 million. The company's quarterly revenue was up 3253.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.41) earnings per share. On average, analysts expect that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on CRSP shares. Barclays upped their target price on CRISPR Therapeutics from $61.00 to $80.00 and gave the company an "equal weight" rating in a research note on Thursday, February 22nd. Needham & Company LLC reissued a "buy" rating and issued a $90.00 price target on shares of CRISPR Therapeutics in a report on Thursday. TheStreet upgraded shares of CRISPR Therapeutics from a "d+" rating to a "c" rating in a research report on Friday, February 23rd. Royal Bank of Canada increased their price target on CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a "sector perform" rating in a research report on Thursday, February 22nd. Finally, Wolfe Research started coverage on CRISPR Therapeutics in a report on Thursday, February 15th. They issued a "peer perform" rating for the company. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $74.75.

Insiders Place Their Bets

In related news, General Counsel James R. Kasinger sold 1,913 shares of the business's stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the transaction, the general counsel now owns 57,371 shares of the company's stock, valued at $4,570,747.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,913 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the completion of the transaction, the general counsel now directly owns 57,371 shares in the company, valued at $4,570,747.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 50,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $60.51, for a total transaction of $3,025,500.00. Following the completion of the transaction, the chief executive officer now owns 187,377 shares of the company's stock, valued at approximately $11,338,182.27. The disclosure for this sale can be found here. Insiders sold 134,410 shares of company stock valued at $9,234,677 over the last quarter. Insiders own 4.10% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.